Clinical trial reports headache frequency shifts after eptinezumab in migraine patients with prior treatment failures, indicating preventive optimization potential.
To determine the shift in headache frequency categories among eptinezumab-treated patients within the DELIVER clinical trial.
No takes yet. Share an insight, caveat, or question.
Starling et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: